December 2, 2020 -- Frontier Medicines and AbbVie entered into a $55 million research and development partnership to deliver cancer and immunological disease treatments.
Under the multiyear, multiprogram agreement, Frontier's chemoproteomics platform, which identifies small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets, will be used.
AbbVie will pay Frontier an upfront cash payment of $55 million, and Frontier will be eligible to receive additional milestone payments up to $100 million within the first 12 months of the collaboration. AbbVie also will reimburse Frontier's research and development costs through specific stages of preclinical development.
Copyright © 2020 scienceboard.net